Why did Jardiance change their commercial actress?
_Understanding the casting switch behind the Jardiance campaign and what it reveals about pharmaceutical marketing_
(By Carmichael Phillip)
The original spokesperson: Deanna Colón
The national ad campaign for the prescription diabetes medication Jardiance featured Deanna Colón, a singer‑songwriter and vocal coach, as the face of the spot. She appears in the commercial singing and dancing, delivering the tagline about lowering A1C and “a little pill with a big story to tell.”
Colón has a background that includes appearances on reality television, vocal coaching, and songwriting.
The campaign’s jingle and upbeat choreography made the spot memorable—but also divisive, as it shifted the conventional tone of a drugadvertisement to something more musical and stylised.
What triggered the change: public reaction and brand feedback
The switch in spokesperson came when the brand introduced a new actress, Rachel Strutt, in January 2024.
What factors led to this? Several intersecting issues help explain the shift:
Polarised audience response: The original commercial featuring Deanna Colón drew a strong, mixed response. While many viewers recognised the ad, others criticised its tone, the jingle, her performance, or the representation of diabetes in a musical format.
Critique regarding fit for medication message: Some commentators pointed out that the upbeat, musical style may not align with the seriousness of type 2 diabetes and pharmaceutical treatment. NickiSwift’s piece notes that critics felt the “campy, dancing number” diluted the gravity of the condition.
Online backlash and personal attacks: Deanna Colón also faced weight‑based criticism and harsh online commentary, as reported in outlets like The Washington Post. These hostile reactions, while not the only reason for the change, may have influenced the brand’s decision given their sensitivity to reputational risk.
Marketing refresh strategy: Advertising firms often refresh campaigns periodically to prevent viewer fatigue, refresh brand perception, or pivot messaging. In the case of Jardiance, shifting the cast may have been part of a broader strategic update. ScreenRant suggests the brand responded to the internet reaction by bringing in Rachel Strutt.
The role of healthcare advertising and brand strategy
When a prescription drug like Jardiance is being advertised, marketers must balance multiple priorities: regulatory compliance, efficacy and safety messaging, brand differentiation, and viewer engagement. Changing an actress can reflect adjustments in any of these dimensions:
Regulatory & messaging considerations: Pharma ads must cover risks, benefits, side‑effects, and disclaimers. The tone and delivery must align with these requirements. If the public response suggests the tone undermines credibility, a change may be warranted.
Brand‑identity alignment: Jardiance may have wanted to reposition its message‑ for example, shifting from a highly musical, upbeat style to something considered more “serious” or inclusive. The actress and her portrayal are central to that.
Audience feedback & market research: Brands monitor viewer sentiment, social‑media commentary, and perhaps measured recall or brand‑favorability. If one version is underperforming or generating negative sentiment, a pivot is a logical step.
Talent contracts & lifecycle: Advertising campaigns often have a lifespan. The original contract with the actress may have been for a specific campaign period, after which the brand chooses to recast as part of a new phase. Although not always publicly disclosed, this is standard industry practice.
Widget not in any sidebars
What we do know from open sources
Deanna Colón starred in the original Jardiance commercial, which began airing circa April 2023.
The new actress, Rachel Strutt, appeared in the campaign beginning January 2024, according to ads databases and media commentary.
In an Instagram message, Colón stated: “Guess what, onward and upward, but you be nice to this new lady. Don’t you send her any hate crap.” This suggests the brand‑switch was known publicly and the actor herself acknowledged it.
Media commentary links the casting change to online criticism of the first ad performance and a desire by the brand to refresh their approach.
Widget not in any sidebars
What we don’t know (yet) and what remains speculative
We don’t have a public statement from the pharmaceutical company (or its ad agency) saying “We replaced the actress because of X.” The reasons remain inferred rather than officially confirmed.
The full internal metrics (brand‑health data, focus‑group feedback, recalling scores) that prompted the change are not publicly available.
We don’t know exactly how much the reaction to the first ad (online commentary, social media outrage) influenced the decision, vs. the normal lifecycle of an ad campaign.
We don’t have confirmation of any contractual or legal aspects (e.g., talent availability, renegotiation, scheduling) that may have contributed to the change.
Widget not in any sidebars
What this switch reveals about pharma marketing & modern ad campaigns
This case offers several lessons for how major brands — especially in the regulated space of healthcare — manage talent and messaging:
Talent matters: Audiences associate an ad actor strongly with the brand. When sentiment toward the actor becomes negative (for any reason), it can impair brand perception. The Jardiance change shows that even in highly regulated sectors, talent choices are subject to ROI.
Public reaction has impact: Unfavourable or polarised public response to an ad can prompt brand changes. Social media and forums (e.g., Reddit) may influence decisions more than might be obvious at first glance.
Tone‑versus‑topic balance: A prescription drug ad needs to strike a careful tone — not too casual, not too scary. When the tone veers too far toward entertainment (e.g., singdance routine), it may raise concerns about appropriateness. The shift in 2024 suggests Jardiance sought a different tone.
Campaign refresh strategy: Recasting talent is a standard part of the lifecycle of advertising, enabling new messages, formats and relevance. For Jardiance, the change may have aligned with a new phase of their campaign.
Actor empowerment and response: Deanna Colón made public remarks encouraging kindness to her replacement, showing awareness of personal impact and the online dimension of modern advertising.
Widget not in any sidebars
Conclusion: Why did Jardiance change their commercial actress?
In short: The switch from Deanna Colón to Rachel Strutt appears to have been driven by a combination of factors — notably audience reaction to the original ad (tone, performance, representation), the need to refresh the brand campaign, and perhaps normal advertising‑lifecycle considerations. While the company has not publicly detailed “We replaced her because…,” commentary from media outlets and the actor herself provide credible insight.
Thus, if you’re wondering why Jardiance changed their commercial actress, the answer is: To recalibrate the campaign’s tone and connection with viewers, likely in response to viewer feedback and to reposition the brand’s health‑message strategy.
Acting Magazine Newsletters
Never miss out on the best from Acting Magazine.